I want to congratulate Dr. Watanabe et al. for their study on the upstaging to invasive ductal carcinoma (IDC) after mastectomy for ductal carcinoma in situ (DCIS) [1] . They reported that 22.6% of 226 DCIS lesions were upgraded to IDC after mastectomy, and the prevalence of macrometastasis of sentinel lymph nodes (SLNs) was 0.9%. I would like to make two comments on this study. First, the authors believed SLN biopsy for patients undergoing mastectomy with a preoperative diagnosis of DCIS was overtreatment based on the fact that the prevalence of SLN metastasis was low and the long-term outcome was excellent. However, although the reported 5-year recurrence-free survival was as high as 99.5%, I noticed the median follow-up period was only 31 months. The survival might be biased with a large ratio of censored data. Moreover, three out of five patients with SLN metastasis were post-operatively pathologically diagnosed as DCIS, indicating that the micro-invasive component were likely to be missed in the pathological test in this study, not only for original lesions, but also for SLNs. As a result, the rate of upstaging and SLN metastasis could both be underestimated. Second, since the surgical procedures were decided by patients themselves, I wonder how many of the included lesions could alternatively be treated by breast-conserving surgery and how many were lesions with a wide range of micro-calcifications or suspected intraductal spreadings. It would be essential to know if there were any differences in rates of upstaging and/or SLN metastasis between these two types of patients.
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